Australia markets closed
  • ALL ORDS

    7,649.30
    -32.00 (-0.42%)
     
  • ASX 200

    7,342.60
    -27.60 (-0.37%)
     
  • AUD/USD

    0.7277
    -0.0022 (-0.29%)
     
  • OIL

    73.45
    +0.15 (+0.20%)
     
  • GOLD

    1,756.30
    +6.50 (+0.37%)
     
  • BTC-AUD

    61,832.92
    +879.08 (+1.44%)
     
  • CMC Crypto 200

    1,122.46
    +13.54 (+1.22%)
     
  • AUD/EUR

    0.6199
    -0.0011 (-0.18%)
     
  • AUD/NZD

    1.0324
    +0.0011 (+0.10%)
     
  • NZX 50

    13,259.55
    -46.37 (-0.35%)
     
  • NASDAQ

    15,316.58
    +140.07 (+0.92%)
     
  • FTSE

    7,048.81
    -29.54 (-0.42%)
     
  • Dow Jones

    34,764.82
    +506.50 (+1.48%)
     
  • DAX

    15,514.93
    -129.04 (-0.82%)
     
  • Hang Seng

    24,192.16
    -318.82 (-1.30%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     

Hepatitis C Drug Pipeline Market Research Report 2021 - ResearchAndMarkets.com

·4-min read

DUBLIN, August 05, 2021--(BUSINESS WIRE)--The "Hepatitis C - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This Hepatitis C - Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hepatitis C pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C.

Hepatitis C Emerging Drugs Chapters

This segment of the Hepatitis C report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis C Emerging Drugs

TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic hepatitis C virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.

SH229: Nanjing Sanhome Pharmaceutical

SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of hepatitis C virus infection.

Hepatitis C: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis C drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hepatitis C

There are approx. 20+ key companies which are developing the therapies for Hepatitis C. The companies which have their Hepatitis C drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.

Phases

This report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Hepatitis C pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis C: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C drugs.

Hepatitis C Report Insights

  • Hepatitis C Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Hepatitis C Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Hepatitis C drugs?

  • How many Hepatitis C drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis C?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatitis C therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Hepatitis C and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Dongguan HEC TaiGen Biopharmaceuticals

  • Nanjing Sanhome Pharmaceutical

  • PharmaEssentia

  • HEC Pharm

  • Atea Pharmaceuticals

  • AllaChem

  • HepC

  • Sunshine Lake Pharma

  • GeneCure Biotechnologies

  • Therapure Innovations

  • Adaptimmune

  • Orgenesis

  • Dekk-Tec

Key Products

  • TG-2349

  • SH229

  • Ropeginterferonum alfa-2b

  • Yimitasvir

  • AT 527

  • AV4025

  • HC-001

  • HEC 74647PA

  • Prophylactic HCV vaccine

  • TBI-301

Research program: T-cell therapies

Research programme: antiviral vaccines

  • IFN alpha CS(g)

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/6a9xhp

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005434/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting